Botulinum toxin for depression: Does patient appearance matter? - 18/12/15
Doi : 10.1016/j.jaad.2015.08.051
Jason S. Reichenberg, MD a, b, ⁎ 
, Aaron J. Hauptman, MD a, Henry T. Robertson, PhD a, b, Eric Finzi, MD, PhD c, Tillman H.C. Kruger, MD d, M. Axel Wollmer, MD e, Michelle Magid, MD a
, Aaron J. Hauptman, MD a, Henry T. Robertson, PhD a, b, Eric Finzi, MD, PhD c, Tillman H.C. Kruger, MD d, M. Axel Wollmer, MD e, Michelle Magid, MD a a University of Texas at Austin, Dell Medical School, Austin, Texas
b Seton Family of Hospitals, Austin, Texas
c Chevy Chase Cosmetic Center, Maryland
d Center of Mental Health, Hannover Medical School, Germany
e Asklepios Clinic North–Ochsenzoll, Hamburg, Germany
∗Correspondence to: Jason S. Reichenberg, MD, Seton Family of Hospitals, 313 E 12 St, Suite 103, Austin, TX 78701
| Funding sources: None. |
|
| Disclosure: Dr Magid received a research grant from the Brain and Behavior Institute, National Alliance for Research on Schizophrenia and Depression Young Investigator award, to fund one of the studies on which these data are based (grant number 17648). The grant went to Seton Family of Hospitals, which then provided salary support to Dr Magid for that research. After completion and as a result of the study, Dr Magid became a consultant with Allergan in November 2012 to discuss study findings. Dr Reichenberg's spouse (Dr Magid) became a consultant with Allergan in November 2012. Dr Kruger received honoraria for talks from Servier and Lundbeck. These activities were unrelated to the study. In April 2012, after completion and as a result of his initial study on botulinum toxin for depression, he became a member of an advisory board with Allergan. Dr Wollmer has received financial support for research through his institution, Asklepios Hamburg GmbH. He also received honoraria for talks from Merz, Novartis, Lundbeck, and Eli Lilly. These activities were unrelated to the study. In April 2012, after completion and as a result of his initial study on botulinum toxin for depression, he became a consultant and a member of an advisory board with Allergan. Dr Hauptman has received financial support for research through his institution for a study unrelated to this subject. Dr Finzi has received a patent to treat depression with BTA. Dr Robertson has no conflicts of interest to declare. |
|
| Preliminary data from this paper were presented at the Texas Dermatological Society Meeting in Austin, Texas on May 1, 2015. |
|
| The studies upon which the data used in this article are based was approved by the Seton Family of Hospitals institutional review board (IRB) (Dr Magid), the Quorum Review IRB (Dr Finzi), and the Ethics Committee of Basel (Dr Wolmer). Each trial was registered under clinicaltrials.gov under study numbers NCT01392963, NCT01556971, and NCT00934687, respectively. |
© 2015
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 74 - N° 1
P. 171 - janvier 2016 Retour au numéro
Article précédent
- Skin diseases associated with Agent Orange and other organochlorine exposures
- Andrew T. Patterson, Benjamin H. Kaffenberger, Richard A. Keller, Dirk M. Elston
- A randomized, controlled, prospective clinical study comparing a novel skin closure device to conventional suturing
- Hadeel Mitwalli, Christopher Dolan, Robert Bacigalupi, Hooman Khorasani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?